Radiation Not Tied to Improved Survival in Advanced NSCLC

Share this article:
Radiation Not Tied to Improved Survival in Advanced NSCLC
Radiation Not Tied to Improved Survival in Advanced NSCLC

MONDAY, Feb. 13 (HealthDay News) -- Postoperative radiation therapy (PORT) is not associated with improved survival for elderly patients with N2 non-small-cell lung cancer (NSCLC), according to a study published online Feb. 13 in Cancer.

Juan P. Wisnivesky, M.D., Dr.Ph., of the Mount Sinai School of Medicine in New York City, and colleagues used data from the Surveillance, Epidemiology, and End Results (SEER) registry linked to Medicare records to identify 1,307 patients who had stage III NSCLC with N2 lymph node involvement, diagnosed between 1992 and 2005. Survival of patients who did and did not receive PORT was compared used propensity scoring methods and instrumental variable analysis.

The researchers found that 710 patients (54 percent) were treated with PORT. PORT was not associated with improved survival in patients with N2 disease (hazard ratio, 1.11; 95 percent confidence interval, 0.97 to 1.27), based on propensity score analysis. Similar results were seen on restricting analyses to patients who did or did not receive chemotherapy and patients who received intermediate-complexity or high-complexity radiotherapy. Additionally, similar results were found when analyses were repeated adjusting for time trends in the use of other lung cancer treatments. The absolute improvement in one-year and three-year survival with PORT was −0.04 and −0.08, respectively, based on the instrumental variable estimator.

"The current data suggested that PORT is not associated with improved survival for elderly patients with N2 disease. These findings have important clinical implications, because SEER data indicate that a large percentage of elderly patients currently receive PORT despite the lack of definitive evidence about its effectiveness," the authors write.

One author disclosed financial ties to pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

ESMO: Herceptin may be best option for HER2 breast cancer treatment

ESMO: Herceptin may be best option for HER2+ ...

Drug should remain standard of care for HER2-positive tumors, according to new research.

ESMO: Combination treatments increase metastatic melanoma survival

ESMO: Combination treatments increase metastatic melanoma survival

Studies show improved progression-free melanoma survival for both cobimetinib combined with vemurafenib, and dabrafenib combined with trametinib.

Lung infections may lessen chance of detecting lung cancer

Lung infections may lessen chance of detecting lung ...

Certain conditions make it harder to reliably detect tumors, and regions with locally-endemic infectious lung diseases pose an added hurdle for lung cancer detection.